The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Taken the opportunity to top-up this morning. Expected dip in sp. Unremarkable report. Drop in revenues due to one off payments received last year, however recurring revenue payments in Europe are up 150%. Given it was H1 report rather than a trading/sales update I didn't expect a great deal of detail about Accrufer progress.
Suspect there may be a top-up opportunity tomorrow. H1 will include a number of outgoings in recruiting sales reps for the US Accrufer launch, but no early sales figures from the July commencement of course. Massively undervalued sub 50p.
Encouraging the Korean CEO stating he will provide Accrufer as first line treatment for IDA. This is the hope for most privatised healthcare markets. My view is it will not make first line treatment in the UK due to cost - as Ferrous Sulphate and Ferrous Fumarate (current first line treatments) are off-license in the UK and therefore dirt cheap.
Encouraging to see a revenue stream will be coming from Korea. Older Koreans have a higher incidence of anaemia compared to relative populations in the developed world, so potentially a large market.
Onwards and upwards
Lovely RNS. Not technically independent, as the study was funded by STX. The methodology is sound however. An equivalance study would be preferable from a medical perspective, but this is encouraging for both patients and shareholders. It's noteworthy that CKD patients who have anaemia, do not necessarily have iron deficiency. Their anaemia is usually down to lack of bone marrow stimulation (EPO loss). Around 5% of CKD patients have iron deficiency anaemia, compared to 25-30% of CKD patients who have anaemia due to lack of EPO. Nonetheless, 5% of CKD patients is a huge number who would potentially benefit from Accrufer. Really promising stuff
@shandypants2. As you suggest, prescription tracking data is available to 'Health Information Organisations', and due to its pseudonymised nature is not publicly available. The UK equivalent data protection legislation is GDPR. Take a look at doi: 10.1007/s11606-008-0630-0 "Prescription Tracking and Public Health", Adriane Fugh-Berman, Journal of General Internal Medicine, 2008.
For this to impact share price would potentially suggest some insider knowledge. But when has that every stopped those in their respective financial institutions.
Bonne chance.
Short term:
Partnership with quantum computing agency
Partnership with UK based cryptography expert
Testing first set of existing optimisations in cryptocurrency mining
Commencement of mining
Long term:
Intellectual property patents of quantum mining process
Sipiem court hearing
Very promising
A question for those more financially literate than myself. If Path were invested pre-IPO in a company via a third party platform (just an example - Seedrs), and were considered significant holders (>3%) as a result of that, would a TR1 need to be issued by Path on that basis, despite that investment being made prior to an IPO? Or is a TR1 required only if there is 'change' in significant holding, ie if Path were to buy or sell shares post-IPO?
Thanks to holders for your advice.
One suspects the Accrufer launch news was already priced into the current trading value, hence not a huge leap today. It would be pleasing to see it hold above 60p but with such a narrow spread, it may be pegged back over the next week. Sales figures will be very welcome in due course. Huge promise with this product.
Another late TR-1 coming out of the woodwork. Quelle surprise! Mr RKB has put the fear into large shareholders. Chapeau, good sir.
Always a pleasure to engage in stimulating and productive conversation, gentlemen.
The benefit of these rigs being located in a shipping container is in the mobility of it. Currently located in Serbia (CLP RNS 1st Feb 2021), it could be easily transported to a location where green energy supply was more plentiful. I would speculate the rigs would stay there for now, and the efficiencies are being focussed on computing gains for now, before eventually moving to a green location.
First link was for *************interviews .com webpage which you can find easily with the rest of the html address.
@intothedeep
https://www.***************************/clear-leisure-plc-bitcoin-mining-serbia/412747071
https://www.lse.co.uk/ShareChat.asp?ShareTicker=CLP&share=ClpL&page=90 - for more background around the time.
Have a look at CLP RNS 9th March 2018, and 11th July 2018. The data centre was then acquired in entirety by 23rd August 2019.
I cannot find evidence we no longer own these mining rigs (without spending hours reading all the RNSs) - very happy to be corrected on this by other shareholders.
It would seem this HL issue has been assigned a low priority for their IT department. The last price quoted on their app is from 27th May (163p). The telephone broker was able to confirm today's correct price (145p) and my purchase was confirmed via fill/kill order. Not quite their usual standard but Aquis is the forgotten child after all. C'est la vie.
I suspect many of these sells reported today are in fact buys. Many investors here will be awaiting the VoyagerLife IPO, in this otherwise dormant company, similar to those involved with Greencare Cap who also have an interest in a crescendo CBD market.
I wonder when market traders will learn integrity? Probably around the same time Margaret Thatcher takes up tap dancing (RIP).
Best of luck.